Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

Summary

This phase II trial studies how well ixazomib citrate works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cells damage the host tissue. Ixazomib citrate may be an effective treatment for chronic graft-versus-host disease.

Timeline

Start

2015-12-08

Primary completion

2018-01-05

Completion

2018-06-27

Drugs

Indications